Top Page
Telix Pharmaceuticals
(Sydney:TLX)
Telix Pharmaceuticals (TLX) vs. iShares MSCI Australia ETF (EWA)
Telix Pharmaceuticals Business Overview & Revenue Model
Telix Pharmaceuticals Earnings Call Summary
Telix Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19B | 783.21M | 502.55M | 160.10M | 7.60M | 5.21M |
| Gross Profit | 674.14M | 509.68M | 314.39M | 29.34M | -29.77M | -16.88M |
| EBITDA | 85.71M | 92.55M | 22.97M | -92.84M | -70.07M | -54.20M |
| Net Income | 34.76M | 49.92M | 5.21M | -104.08M | -80.51M | -44.89M |
Balance Sheet | ||||||
| Total Assets | 1.19B | 1.52B | 398.30M | 255.35M | 109.81M | 157.82M |
| Cash, Cash Equivalents and Short-Term Investments | 207.16M | 710.35M | 123.24M | 116.33M | 22.04M | 77.94M |
| Total Debt | 418.25M | 581.45M | 17.45M | 10.45M | 2.54M | 2.21M |
| Total Liabilities | 768.01M | 948.22M | 249.39M | 178.44M | 106.17M | 78.81M |
| Stockholders Equity | 421.94M | 568.21M | 148.91M | 80.01M | 2.16M | 79.02M |
Cash Flow | ||||||
| Free Cash Flow | 5.92M | 9.00M | 13.09M | -77.83M | -60.67M | 1.64M |
| Operating Cash Flow | 36.39M | 43.03M | 23.88M | -63.97M | -59.33M | 1.96M |
| Investing Cash Flow | -497.38M | -135.17M | -25.49M | -17.00M | -2.73M | -1.09M |
| Financing Cash Flow | 630.70M | 638.92M | 10.19M | 174.96M | 2.85M | 34.12M |
Telix Pharmaceuticals Technical Analysis
Telix Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$634.54M | 17.50 | 15.90% | 0.38% | 7.76% | 1.55% | |
71 Outperform | AU$2.43B | 16.55 | 54.79% | ― | 12.35% | 26.73% | |
65 Neutral | AU$3.81B | 224.90 | 3.21% | ― | 60.23% | -66.98% | |
55 Neutral | $3.94B | -21.82 | -18.95% | ― | 198.58% | 3.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$91.48M | -9.23 | -49.72% | ― | ― | 10.78% | |
49 Neutral | AU$641.07M | -10.31 | -35.86% | ― | ― | -19.21% |
Telix Pharmaceuticals Corporate Events
Telix Pharmaceuticals has announced the lapse of several classes of conditional securities, including 45,000 share rights (TLXAP), 326,334 share appreciation rights (TLXAO), and 84,896 US performance share appreciation rights (TLXAW), all of which ceased on 30 October 2025 after their vesting conditions were not met or became incapable of being satisfied. The cessation of these rights reduces potential future equity dilution and indicates that certain performance or service conditions tied to these incentives were not achieved, marginally simplifying the company’s capital structure and refining the alignment between management incentives and shareholder outcomes.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$25.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals has released the investor presentation that Managing Director and Group CEO Dr. Christian Behrenbruch will deliver at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with the session to be webcast live and available on demand via the company’s investor relations site. Alongside the conference materials, Telix has also published a comprehensive overview of its therapeutic pipeline assets and confirmed it will report fourth-quarter 2025 financial results on 20 January 2026, signalling an active period of investor engagement and increased transparency around its development programs and financial performance.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$25.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals has notified the market of the issuance of 2,501,179 unquoted share appreciation rights under its employee incentive schemes, comprising 742,992 Telix share appreciation rights and 1,758,187 US performance share appreciation rights, both dated 24 October 2025. The move underscores the company’s continued use of equity-based compensation to align staff incentives with shareholder interests, potentially strengthening talent retention and management focus on long-term value creation without immediate dilution to quoted share capital.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$28.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals has applied to the ASX for quotation of a small number of additional ordinary fully paid shares, totaling 41,161 securities, issued on various dates in November and December 2025 following the exercise of options or conversion of other securities. The incremental listing reflects routine capital management activity and a modest expansion of the company’s quoted share base, with limited immediate impact on overall capital structure but signalling ongoing execution of equity-linked incentives or financing arrangements.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$28.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals reported strong top-line Phase 3 data from its Illuccix (TLX591-CDx) prostate cancer imaging trial in Chinese patients, with a patient-level positive predictive value of 94.8% and treatment plans altered in more than two-thirds of participants, paving the way for a near-term New Drug Application in China’s rapidly expanding prostate cancer and nuclear medicine market in partnership with Grand Pharma. The company also outlined progress on U.S. regulatory pathways for its other imaging agents, with an NDA resubmission for glioma PET tracer TLX101-CDx being finalised following constructive FDA feedback, and alignment reached with the FDA on addressing chemistry, manufacturing and controls issues for TLX250-CDx, including an additional meeting in January to confirm data requirements for commercial-scale manufacturing comparability, underscoring Telix’s efforts to stabilise and expand its precision medicine portfolio while maintaining expanded access programs for patients.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals has provided an update on its ProstACT Global Phase 3 study involving TLX591, a prostate cancer therapy candidate targeting metastatic castration-resistant prostate cancer (mCRPC). The company has successfully completed Part 1 of the study and has now initiated Part 2 across several countries, following positive safety and clinical results. This study marks a significant milestone in the development of TLX591, as it combines a PSMA-targeted radio antibody-drug conjugate with existing Standard of Care treatments, promising a unique therapeutic alternative with fewer adverse effects. Expansion into additional global jurisdictions, including Europe, is underway, enhancing Telix’s industry positioning and reinforcing its commitment to advancing innovative oncology solutions.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$17.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals Limited has updated its Securities Dealing Policy effective from December 11, 2025, in compliance with ASX Listing Rule 12.10. This update reflects the company’s ongoing commitment to regulatory compliance and may impact its operations by ensuring transparency and integrity in securities dealings, potentially affecting investor confidence and stakeholder engagement.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$28.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals has announced the dosing of the first patient in Part 2 of its ProstACT Global Phase 3 study, which evaluates the prostate cancer therapy candidate TLX591 in patients with metastatic castration-resistant prostate cancer. This trial is notable for combining a PSMA-targeted radio antibody drug conjugate therapy with standard care treatments. The study is expanding globally, with recruitment ongoing in several countries, and plans to submit data to the FDA to further expand the trial in the U.S. This milestone is significant for Telix’s prostate cancer therapeutics pipeline and may enhance its industry positioning by potentially offering a new treatment option with fewer adverse effects compared to existing therapies.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals announced the release of 45,584 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business. This release of shares is a strategic move following the acquisition, potentially impacting Telix’s market positioning by enhancing its operational capabilities in the radio-guided surgery sector.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals announced the release of 1,649,037 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical’s SENSEI® radio-guided surgery business. This release, scheduled for November 3, 2025, marks a significant step in the integration of Lightpoint Medical’s technologies, potentially enhancing Telix’s market position in the field of minimally invasive and robotic-assisted surgery.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
Telix Pharmaceuticals reported a significant revenue increase of 53% year-over-year for Q3 2025, reaching $206 million, and upgraded its FY 2025 revenue guidance to $800-820 million. The company achieved full reimbursement for Gozellix in the U.S. and expanded its Illuccix product approval to 19 European markets. These developments, along with ongoing clinical trials and strategic market launches, position Telix strongly in the precision medicine sector, enhancing its competitive edge and operational capabilities.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.